Early Aspirin Discontinuation Following PCI in Low-Risk Acute MI Patients: The TARGET FIRST Trial
The TARGET FIRST trial demonstrated that among low-risk acute myocardial infarction (AMI) patients who remained free of ischemic or bleeding events during 1 month of dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) implantation, switching to P2Y12 inhibitor monotherapy was non-inferior to continuing DAPT for cardiovascular and cerebrovascular outcomes and reduced the risk of clinically relevant bleeding by 54%, according to a study presented by Dr. Giuseppe Tarantini, University of Padova, Italy, in the Hot Line session at ESC Congress 2025.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
